http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2273847-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_201743fd9120bd252238a424f46568ea |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 1997-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac5718c0697b57851d4ae1ee0b3704ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae6e1f215244375458d180e4209e1f94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08035ed23f78dabf241dd7c2322a2f39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e556f8948c6880e4d1d7bfa5f8e5a8 |
publicationDate | 1998-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2273847-A1 |
titleOfInvention | Diagnosis of disease state using mrna profiles |
abstract | Disclosed are diagnostic techniques for the detection of a human diseased state. Genetic probes and methods useful in monitoring the progression and diagnosis of the disease state are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Further disclosed is a multivariate diagnostic model for prostate cancer in a population of men with moderately elevated total serum PSA (>= 2.0 ng/ml). Results of quantitative serum assays for the UC325 gene product [Interleukin-8 (IL-8)], total prostate specific antigen (t-PSA), as well as Free/Total (f/t PSA) ratios were combined to enhance the sensitivity of prostate cancer diagnosis in a defined urologic population diagnosed either organ-confined prostate cancer (clinical stage A & B), non-organ-confined prostate cancer (clinical stage C or D) or benign prostatic hyperplasia (BPH). The additional ability of UC325 gene product serum levels to accurately stage prostate cancer independently of t-PSA of f/t PSA is disclosed. |
priorityDate | 1996-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 666.